Background: Perioperative discontinuation of antiplatelet therapy (APT) in patients with coronary stents has been associated with major adverse cardiac events. Our aim was to analyse the perioperative management of APT in such patients and its relationship to the incidence of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding events (MBE) in noncardiac surgery. Methods: We completed a prospective multicentre observational study of patients with coronary stents undergoing noncardiac surgery in 11 hospitals in Spain. The main objectives were to record perioperative events and prospectively analyse the management of APT, and to assess whether the different preoperative APT regimens were associated with MACCE and MBE. Results: Of 432 surgical procedures studied, 15% experienced a perioperative MACCE and 37% a MBE. Overall mortality was 3.0%. Presurgical APT was prescribed in 95% of procedures, and was preoperatively discontinued in 15%. Surgery was urgent or emergent in 22% of patients, 31% were ASA IV, and 38% had a Revised Cardiac Risk Index of IV. MACCE were related to recent myocardial infarction (P¼0.038), chronic kidney disease (P<0.001), insulin-dependent diabetes (P¼0.006) and no preoperative APT (P¼0.018). MBE also increased MACCE risk (P<0.001). We found statin therapy (P¼0.049) and obesity (P¼0.016) to be protective factors for MACCE. Conclusions: Patients with coronary stents undergoing noncardiac surgery suffer a high incidence of perioperative adverse events, even with perioperative APT. Major adverse cardiac and cerebrovascular events are mainly related to previous medical conditions and perioperative major bleeingn events. Our findings should be treated with caution when applied to an elective surgery population. Clinical trial registration: NCT01171612.
Editor's key points
The association of discontinuation of preoperative antiplatelet therapy with major bleeding, cardiac and cerebrovascular events was assessed in a multicentre prospective observational study. Of the 432 subjects with coronary stents undergoing noncardiac surgery, 15% had an adverse event and 3% died. Patients with coronary stents undergoing noncardiac surgery appear to be at high risk for adverse events even when receiving perioperative antiplatelet therapy.
Percutaneous coronary intervention (PCI) with stent implantation has become the most frequent therapeutic revascularization procedure in patients with coronary artery disease (CAD). Dual antiplatelet therapy (APT) with aspirin and P2Y12 inhibitors are needed to prevent or reduce stent thrombosis until stent endothelialisation, which takes between one to 12 months, depending on the type of stent and its indication. 1, 2 Premature discontinuation of dual APT has been identified in several observational studies as the most important predictive factor for stent thrombosis. 3 A common reason for discontinuing APT is the need for noncardiac surgery, estimated to be required during the first yr post-implantation by nearly 5% of patients with bare metal stents (BMS), 4 and by 4.4% to 7% of patients with drug eluting stents (DES). 5 Moreover, a review of the incidence of adverse events after noncardiac surgery found stent thrombosis rates from 0% to 18% in patients with BMS, and from 0% to 7% in patients with DES. 6 Although it is rightly assumed that there is an increased risk of bleeding in the setting of noncardiac surgery in patients under APT, the actual incidence is unclear, as studies report varying rates, in part as a result of different bleeding endpoint definitions. 6 Currently available clinical practice guidelines recommend delaying elective surgery in patients who require dual APT up to at least four weeks after BMS, and up to six months to one yr after DES implantation whenever possible.
7e12 This is supported by a systematic review of the literature showing that the rate of perioperative major cardiac events in patients with DES is higher when performed during the first yr postimplantation than afterwards (0%-18% us 0%e12%, respectively). 13 The incremental risk of adverse cardiac events after noncardiac surgery among post-stent patients is highest in the initial six months after implantation and stabilizes at 1% after this period. 14 In the event that the surgery cannot be postponed beyond the recommended time for dual APT, there is no general consensus on the optimal time for the discontinuation of dual APT preoperatively. Guidelines on perioperative APT management in patients with coronary stents assess the risk of stent thrombosis vs the risk of surgical bleeding. 7e9 When stopping dual APT is mandatory because of the risk of surgical bleeding in patients in whom the risk of stent thrombosis is high, i.v. bridging therapy with glycoprotein IIb-IIIa inhibitors has been described. 8 According to the 2006 recommendations of the French Society of Anesthesiology and Intensive Care, if withdrawal of antiplatelet agents is necessary, substitution with flurbiprofen (a reversible inhibitor of cyclo-oxygenase with a short half-life) or therapeutic doses of heparin may be indicated, 15 however, randomized clinical trials have revealed conflicting results. 16 In surgery with low or intermediate risk of bleeding, guidelines recommend stopping clopidogrel and continuing aspirin during the perioperative period for patients on dual APT and switching to aspirin for patients on clopidogrel monotherapy. 9 Unfortunately, the level of evidence from clinical trials is limited, and these recommendations are mainly based on expert opinion. Therefore, there is a need for well-designed prospective studies to guide physicians on optimal APT management in patients with coronary stents undergoing surgery. 10 The main objectives of the present study were to prospectively analyse the actual practice of APT management in patients with coronary stents undergoing noncardiac surgery and to assess whether the different perioperative APT regimens are associated with major adverse cardiovascular and cerebrovascular events (MACCE) and major bleeding events (MBE).
Methods
This was a prospective observational multicentre study carried out at 11 hospitals in Catalonia (ClinicalTrials.gov identifier NCT01171612). The protocol was approved by the appropriate Ethics Review Committee (CEIC 2009560) and conducted in accordance with the Declaration of Helsinki. All participants or their legal guardians provided written informed consent before enrolment. All patients fulfilling the inclusion criteria were consecutively recruited from January 2010 to April 2012.
Participants
We recruited all patients aged 18yr with coronary stents undergoing scheduled or emergency noncardiac surgery requiring hospital admission for at least 24 h. All enrolled subjects received general, neuraxial, peripheral nerve block or local anaesthesia and sedation. Exclusion criteria were patients with previous coronary artery bypass graft in an artery with a previous stent, outpatient surgery, pregnant women, and obstetric procedures.
Variables and data collection
We collected patient data and potential preoperative risk factors for MACCE, which included the presence of active cardiac conditions (unstable coronary syndromes; decompensated heart failure; significant arrhythmias; severe valvular disease), clinical risk factors (history of CAD, chronic kidney disease, congestive heart failure, diabetes mellitus [DM] or cerebrovascular disease), and other minor predictors of ischaemic disease (age>70 yr, abnormal electrocardiogram [ECG], nonsinus rhythm, or hypertension). We also collected data concerning the PCI and main features of the stent (type and number of stents, date of implantation). In subjects with more than one stent, we took into consideration the most recently implanted stent to analyse the time interval between implantation and surgery. Data on preoperative pharmacological treatments and data related to the ongoing surgical procedure were also obtained.
The prescribed APT regimen was recorded throughout hospital admission and at 30 and 90 days after surgery. The analysis of preoperative APT withdrawal was done by recording the date of the last dose of APT and the date of surgery. We defined complete withdrawal of APT as the total discontinuation of APT (mono or dual therapy) for at least five days before surgery. Partial withdrawal of APT was defined as the discontinuation of clopidogrel, but not aspirin, for at least five days before surgery by patients on dual APT. We also registered the replacement of antiplatelet drugs by heparin, tirofiban or nonsteroidal anti-inflammatory drugs (NSAIDs). Lowering aspirin dose or replacing clopidogrel (when used as monotherapy) with a low dose of aspirin (without any interruption before surgery) was not considered withdrawal, as the antiplatelet effect was preserved. Moreover, we registered the resumption of APT after surgery. We scrupulously analysed adherence to the current Spanish guidelines published in 2011, 9 taking into account stent type, delay between stent implantation and surgery, surgical priority (emergency, urgent or elective) and haemorrhagic and thrombotic risk. For this purpose we used the current Spanish clinical guidelines management algorithm for patients with coronary stents undergoing noncardiac surgery, shown in Supplementary Figure S1 . We considered patients to be compliant with the guideline if APT management and time interval between stent implantation and surgery were in accordance with the aforementioned algorithm. We also analysed the effect of adherence to guidelines on the occurrence of perioperative events (MACCE and MBE).
The main outcome of the study was the occurrence of at least one MACCE during hospitalisation or at 30 and 90 days after surgery. We defined MACCE as any of the following: cardiovascular death, non-fatal cardiac arrest, any acute coronary syndrome (ACS), stroke, transient ischaemic attack (TIA), congestive heart failure, or new significant arrythmia (previously described in the ANESCARDIOCAT study). 17 during or after surgery, or an intracranial haemorrhage. Neuroaxial haemorrhagic events related to central blockade were also recorded. A secondary goal was to identify potential risk factors for these adverse events. Definitions of perioperative events are described in Table 1 . Data were collected by local investigators at each centre who were trained to fill in a structured questionnaire. Preoperative information was obtained from the preoperative anaesthetic evaluation. Daily consultation of medical records by local researchers identified subjects with postoperative complications and APT resumption after surgery. After discharge, subjects received a phone call at 30 and 90 days after surgery to check clinical status and APT regimen. Data were then transferred to a centralised electronic database case report form, MySQL, by a secure protocol that allowed continuous monitoring and review.
Statistical analysis
Categorical variables were expressed as number of cases and percentages, and continuous variables as the mean and standard deviation (SD). Bivariate analysis was done using Pearson c 2 (or Fisher exact test for small samples) for categorical variables, and by Student's t-test for continuous variables. Multivariate logistic regression analysis was performed to estimate the adjusted odds ratio (OR) and associated 95% confidence intervals (CI) for each independent risk factor for cardiovascular events. The full multivariate logistic regression model included variables with statistical significance set at a P value of <0.1 in the univariate analysis and variables that we considered clinically relevant: gender, time interval between stent implantation and surgery, and no preoperative APT. Then a stepwise procedure with backward elimination was used to retain all significant variables at a P value of <0.05.
Sample size
Most published studies on this topic are retrospective, single centre studies with small sample sizes. The definition of adverse events varies greatly between studies, as does the percentage of such events, making it difficult to estimate an adequate sample size. In an interim analysis, we reported an incidence of MBE up to 41% in patients whose APT was not withdrawn. For these reasons, we assumed the worst casescenario, which consisted of a percentage of perioperative complications of 50%. With a 95% CI, a precision of 5%, and an anticipated replacement rate of 10%, we calculated that a sample size of 427 subjects would suffice.
Assessment of confounding
To evaluate whether confounding was present or not in this study we investigated whether any variable in the multivariate 
Results
We studied 483 surgical procedures in patients with at least one implantable coronary stent undergoing noncardiac surgery. Of these, 51 procedures were excluded because of lack of relevant data or loss to follow-up after hospital discharge. Overall, we analysed data from 432 procedures carried out in 365 patients: 317 had only one surgical procedure, while 48 (13%) underwent more than one surgical intervention during the study period. The recruitment flowchart is shown in Figure 1 . Table 2 shows subject and procedure characteristics. Surgery was considered emergency or urgent in 22% of cases, 31% of subjects were ASA IV, and 38% had a Revised Cardiac Index of IV. We analysed a total of 774 stents (46% DES, 36% BMS and 18% unknown). Almost half of the patients (48%) had more than one coronary stent, and 9.2% had both types. In 67 (16%) procedures, the time interval between stent implantation and surgery was less than one yr, and in 10 cases, surgery was performed within six weeks after stenting (Table 3 ). In 31 of these procedures, APT management was decided on by a multidisciplinary team comprising an anaesthetist, cardiologist, oncologist and surgical specialist. At the time of preoperative evaluation, 412 (95%) of procedures were in patients on some type of APT. For the remaining 20 procedures, 14 subjects were receiving oral anticoagulants and six were not on either APT or anticoagulants. Preoperative APT was maintained in most procedures (85%), with a median time of preoperative withholding of zero days for aspirin and four days for clopidogrel. Preoperative APT management and replacement therapy are shown in Table 4 . Complete withdrawal of APT (any antiplatelet drug) was observed in 5.8% of cases (6% of those on aspirin therapy, 19% on clopidogrel and 0.8% on dual APT). Of those with preoperative clopidogrel, replacement with low dose aspirin was used in 25 cases, low-molecular-weight heparin in three, and trifusal in one. In subjects undergoing surgery with preoperative dual APT, partial withdrawal (stopping clopidogrel for at least five days while maintaining aspirin) occurred in 32%. Bridging therapy with tirofiban was used in one procedure, in a subject on dual APT with high bleeding and cardiac risk. We recorded the reduction in preoperative high-dose aspirin (300 mg day e1 , in subjects with previous stroke or TIA) to 100 mg in 17 subjects on aspirin monotherapy and two on dual APT. No preoperative regimen of either prasugrel or ticagrelor was recorded. Adherence to the Spanish guidelines 9 was considered appropriate in 373 procedures (90%). With regard to other treatments, the most usual prescribed drugs were statins (83%), followed by beta-blockers (66%).
Incidence and management of perioperative events
At 90 days after surgery, MACCE had occurred in 63 (15%) of the surgical procedures with all-cause mortality of 3% (n¼13, one cardiovascular death), and most deaths (n¼10) occurring during the first 30 days after surgery. In-hospital MACCE was associated with a higher risk of new MACCE after discharge (OR ¼ 14.1; CI 95%¼6.2-32.1). The incidence of acute myocardial infarction (AMI) and cardiovascular death was 2.8%, 50% of which were after discharge. The incidence of overall MBE was 37% (n¼161), all during admission. There were no 483 SP in patients with implanted coronary stents undergoing scheduled or emergency non-cardiac surgery haemorrhagic events related to neuraxial blockade. Perioperative events recorded during admission and after discharge (90 days after surgery) are shown in Supplementary Table S2 .
We first assessed whether occurrence of MACCE, MBE and mortality were associated with preoperative management of APT. In the univariate analysis of preoperative management and perioperative events (Table 4) , APT withdrawal was not linked to MACCE for any preoperative antiplatelet regimen, nor did either complete or partial preoperative discontinuation of APT increase risk of MACCE.
In subjects with preoperative aspirin monotherapy, complete withdrawal was related to an increase in MBE (OR ¼ 3.0; CI Table S3 ). The variables included in the multivariate analysis are shown in Table 5 . The final model selected five independent predictors for MACCE: recent AMI, lack of any preoperative APT, perioperative MBE, chronic kidney disease defined by estimated glomerular filtration rate (eGFR) and insulin dependent DM. Moreover, we found two protective factors: obesity and preoperative statin therapy (Fig. 2) . Confounding by indication was also evaluated, as patients at greatest risk of MACCE are also those who are most likely to remain on APT.
None of the variables included in the final model proved to modify APT management, except for renal dysfunction (Supplementary Table S4 ). Chronic kidney disease might confound the association between the appearance of MACCE and APT withdrawal, as both variables correlate: a higher percentage of kidney disease patients remain on antiplatelet agents compared with those with eGFR60ml min e1 1.73 m e2 (98% us 92%, P¼0.038) (Supplementary Table S5 ).
Discussion
We assessed the management in actual practice of patients with coronary stents undergoing noncardiac surgery and its consequences on short-and mid-term outcomes. Our registry demonstrates that even though most patients in the centres examined undergo surgery under APT in accordance with guideline recommendations, they are still at high risk for MACCE, although AMI and cardiovascular death occurred in only 12 procedures (2.8%). Adherence to current guidelines was considered appropriate in 90% of subjects, but our results failed to show a better outcome when guidelines were applied.
Our small sample size, the high percentage (64%) of surgeries in which a medical condition prevented delaying surgery, and the low percentage of cases in which guidelines were not adhered to could have influenced this result. It is worth noting the high percentage of subjects on APT at the time of preoperative evaluation (95%), and the low rate of complete withdrawal of APT before surgery (5.8%). In a multicentre study of patients with a recently implanted DES, FerreiraGonzalez found that 14% of patients had interrupted APT in advance, and in such cases surgery and major bleeding were responsible for only 51% of these interruptions. 19 Of the different regimens of replacement therapy registered (8%), some followed current guidelines, while others (heparin or NSAIDs) did not. We thus cannot draw any robust conclusions from these data. The incidence of MACCE in our study was 15%, which is much higher than in the general population undergoing intermediate or high-risk noncardiac surgery (4.3%), according to the results of the ANESCARDIOCAT survey. 17 This was somewhat expected, because of the fact that all subjects enrolled in our cohort had CAD and other clinical risk factors for cardiovascular events. The French RECO study, conducted in 1134 patients with coronary stents undergoing noncardiac surgery, found an overall MACCE incidence of 11%, but it also included diagnostic endoscopic and invasive procedures that could have decreased the incidence of MACCE. 20 Our results show that those patients who were not chronically on APT (4.6%) were at increased risk of MACCE. However,
Recent AMI (<30 days) Factors
Odds ratio (95%CI) even though previous studies showed that complete discontinuation of dual APT before surgery was the main trigger for stent thrombosis and a major cause of MACCE, 1,20,21 we could not confirm these results. This could be explained by the low rate of complete preoperative withdrawal of APT in our population compared with the RECO study, where complete interruption was higher (34% for clopidogrel, 29% for aspirin, and 16% for dual APT). 20 The lower incidence of complete discontinuation in our study was probably as a result of the fact that anaesthetists are now much more aware of the adverse effects of APT withdrawal in patients with stents, and to the high prevalence of the replacement of clopidog-rel with low dose aspirin as guidelines recommend. We found a low incidence of AMI and cardiovascular death (2.8%) at 90 days after surgery. A recent matched cohort study comparing adverse cardiac events in patients with and without stents in the surgical setting found a global incidence of AMI, revascularization and/or death within 30 days after surgery of 5.7% in the stented cohort. 22 The same study also confirmed that the risk for perioperative AMI decreased from 5% immediately after stent placement to 2% at oneyr after stenting. Even though the study was large and included 9391 patients with coronary stents, data were analysed retrospectively and included patients from 2000 to 2010, a period of time in which both stents and perioperative management evolved enormously. This would probably explain the higher incidence of such severe adverse outcomes. 22 In contrast, most of our procedures followed the recommendations of current guidelines with respect to the time interval between stenting and scheduled surgery, 7, 8, 9, 11 which may have contributed to reducing AMI and cardiovascular death. We think that for this same reason, we did not find any relationship between the time interval between implantation, surgery and MACCE. Most of our surgical procedures (84%) were performed more than one yr after stent implantation, so we cannot exclude a possible association between noncardiac surgery and MACCE in patients with more recently implanted coronary stents. We had a high incidence of MBE (37%), which also increased the risk of MACCE. Results from multiple studies show a variable frequency of significant bleeding, in part as a result of different definitions of bleeding endpoints. 6 We also found an increase in MBE when preoperative aspirin was discontinued at least five days before surgery. Although we cannot draw robust conclusions with the low rate of withdrawal in this group, this increase could be related to the actual practice of discontinuing aspirin in patients with high bleeding risk, who were not protected from major bleeding despite the discontinuation of aspirin.
The POISE-2 study demonstrated an increased risk of bleeding in patients on low-dose aspirin and no protective effect with regard to mortality or non-fatal AMI in noncardiac surgery patients. 23 The authors postulated bleeding as a cause of the subsequent mismatch between myocardial oxygen supply and demand, leading to AMI and counteracting the preventive effect of APT. However, the increase in bleeding was observed only in the initiation stratum, and no statistically significant differences in bleeding were found in the continuation stratum (chronic therapy with aspirin). Moreover, only 4.7% of patients in the POISE-2 study had a coronary stent. The REACH registry of patients with vascular disease also showed that patients who experienced serious bleeding had a significantly higher rate of major vascular events. 24 We also believe that bleeding calls for a delay in postoperative APT resumption when there is still a risk of MACCE in patients with stents.
Recent AMI was found to be an independent predictor for MACCE in our study. Recent AMI is considered an active cardiac condition in current guidelines for preoperative evaluation, 8, 25 and elective surgery should be postponed. However, we registered six emergent surgical procedures in patients with a recent AMI. The multivariate regression analysis also found eGFR <60 ml min e1 1.73 m -2 and insulin dependent DM to be independent predictors for MACCE. These findings are consistent with previous literature, 17, 26 as an increased risk of MACCE with the decline of eGFR has also been previously reported. 20, 27, 28 The incidence of renal dysfunction in our study was higher when using eGFR as a measure, instead of serum creatinine alone, which is consistent with previous studies in which eGFR has been shown to be more accurate than creatinine in diagnosing renal impairment. 28 Confounding by indication for preoperative APT withdrawal and MACCE cannot be ruled out entirely in patients with chronic kidney disease. Further studies are needed to assess the management of APT in this type of patient.
The association of obesity and statin therapy with a lower incidence of MACCE is notable. Although obesity is a known risk factor for cardiovascular disease, it has also been observed to confer a survival benefit compared with normal and underweight patients when an acute cardiovascular event occurs, described as the "obesity paradox". 29 The relationship between BMI and mortality in patients undergoing PCI for acute coronary syndrome has been reported to be greater in normal or underweight patients than in those who are obese or overweight. 30 In our study obesity was measured by BMI, and some studies question whether BMI is as good a measure of obesity as body fat percentage.
29e31
Statins are widely used in the prevention of atheromatous disease and its complications, and there is growing evidence that perioperative statin therapy is safe and beneficial in reducing cardiovascular morbidity and mortality. 32, 33 Our study has some limitations that must be acknowledged. Although it was conducted prospectively, this was an observational study. Hidden biases cannot be completely ruled out and the sample size of this study might not have been large enough to control for the complex interaction of confounders that can occur in this clinical setting. It is thus not possible to fully address the potential for confounding with the available data.
The logistic regression did not allow us to either establish or rule out an association between confounders and withdrawal of APT. This can be explained by the low rate of events, which led to a logistic regression with low statistical power. Although we registered a high number of preoperative APT prescriptions, allowing for a comprehensive analysis of perioperative APT management, complete withdrawal was observed in only 5.8% of subjects, which precluded establishing a definite relationship with the occurrence of adverse events. Most of our surgeries were performed after one yr of stent implantation, thus avoiding the period with the highest risk for stent thrombosis. We had a high percentage (83%) of males, which may have led to gender bias, although in the multivariate analysis we did not find gender to be a risk factor. Finally, we did not systematically determine postoperative troponin concentrations and record electrocardiograms. As a result, the rate of AMI may have been underestimated, as silent events would not have been detected. However, our definition of ischaemic cardiac events is broad enough to detect the most clinically relevant complications. We defined MBE as a decrease in haemoglobin equal to or greater than 20 g L e1 , an amount attributable to a modest blood loss plus haemodilution. We determined postoperative haemoglobin concentrations in only 34% of cases. Those patients with no laboratory analysis were considered non-anaemic, so postoperative anaemia may have been underestimated. We registered the last isolated creatinine measurement before surgery, so we acknowledge the possibility that some of those considered to have chronic kidney disease were patients with some degree of acute kidney dysfunction.
In conclusion, we found that patients with coronary stents are still at high risk for MACCE, although most of our subjects underwent noncardiac surgery while on APT, in accordance with current guideline recommendations. The incidence of MACCE was mainly related to previous medical conditions and perioperative MBE. Our study was conducted in a high-risk population, with a high prevalence of non-elective procedures; hence, our findings should be treated with caution when applied to an elective surgery population. In our registry, patients without preoperative APT were at a higher risk of MACCE. Anaesthetists should be especially vigilant with those patients with no previous APT of any type, and bear in mind that APT can be resumed after surgery once haemostasis is confirmed.
